Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, ...

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced the publication of ...

For individuals living with fragile X syndrome — a common genetic disorder that is correlated with autism, causes intellectual disability and more frequently affects male individuals — anxiety, ...

Denise Devine was named a finalist in the 22News Remarkable Women contest for her community service work in Hampshire County.

Marvel Biosciences Corp. (TSXV: MRVL \| OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively M ...

Bile Acid Medicines Sales -- $41 million attributed to CHOLBAM and CTEXLI medicines supported by expanded CTX patient finding ...

Management expects completion of VISTAS study enrollment for Volixibat in PSC in the third quarter of 2025, with data readout ...

Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company") ...

Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered ...

The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials.

Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members ...

Explore how advances in accuracy, throughput and cost are making long-read sequencing more accessible at scale.